Filters
Maternal use of the migraine drug triptans before or during pregnancy does not appear to put infants at risk of developing neurodevelopmental disorders, according to a study.
In the treatment of patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonists (GLP1-RAs) do not increase the risk of psychiatric adverse events or worsen depressive symptoms but rather confer improvements in quality of life (QOL) and eating behaviour, according to the results of a meta-analysis.
The KV7 potassium channel opener azetukalner helps improve symptoms of major depressive disorder (MDD) in adults, according to the results of the proof-of-concept, phase II X-NOVA study.
Intracavernosal injection (ICI) of aviptadil with phentolamine mesylate (AvP) demonstrates efficacy in more than half of the men with refractory erectile dysfunction (ED) who participated in a recent study.
For older adults who received treatment with antipsychotics to manage delirium, medication discontinuation leads to better outcomes, including reduced risks of all-cause rehospitalization and mortality, compared with continued use, according to a study.
Body weight appears to affect a person’s sexual desire, suggests a study.
A significant association exists between refractory gastroesophageal disease (RGERD) and increased methane (CH4) levels, reports a study.
A new mobile application, Bounce Back Now (BBN), may help reduce postdisaster symptoms of post-traumatic stress, depressed mood, and sleep disturbance, according to a study.
A prolonged exposure (PE) therapy with topiramate may significantly reduce symptoms of post-traumatic stress disorder (PTSD) compared with placebo, suggests a study.
A school-based personality-focused intervention shows potential in lowering the rates of substance use disorder (SUD) among adolescents, reports a study.
